| Terminated | Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Non-GCB/ABC Diffuse Large B-Cell Lymphoma, With and Without MyD88 and/or CD79B Mutations | Phase 2 | 2022-06-23 |
| Terminated | NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung | — | 2021-01-19 |
| Completed | Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects Cardiac Safety | Phase 1 | 2020-10-05 |
| Completed | Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy S Drug Interaction | Phase 1 | 2020-09-22 |
| Terminated | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung | Phase 2 | 2020-07-24 |
| Completed | Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis Cystic Fibrosis | Phase 1 | 2020-07-03 |
| Completed | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors Solid Tumors, NSCLC, CRC | Phase 1 / Phase 2 | 2019-06-25 |
| Terminated | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer | Phase 1 / Phase 2 | 2019-05-20 |
| Withdrawn | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) Lymphoma, Non-Hodgkin | Phase 1 | 2019-04-03 |
| Withdrawn | A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Advanced Solid Neoplasms, Lymphoma Neoplasms | Phase 1 | 2018-05-10 |
| Completed | CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcino Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | 2018-04-24 |
| Withdrawn | A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced S Lymphoma, Malignant, Advanced Solid Neoplasms | Phase 1 | 2018-02-28 |
| Completed | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin L Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse, Lymphoma, Follicular | Phase 1 | 2018-02-16 |
| Terminated | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult Ea Advanced Nonhematological Neoplasms | Phase 1 | 2018-01-17 |
| Terminated | TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Diffuse Large B-cell Lymphoma | Phase 2 | 2017-10-10 |
| Completed | CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) Clear Cell Renal Cell Carcinoma | Phase 2 | 2017-09-06 |
| Terminated | A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL) Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Marginal Zone | Phase 1 | 2017-08-01 |
| Completed | Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | 2017-05-01 |
| Completed | A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults Healthy Volunteers | Phase 1 | 2016-10-01 |
| Terminated | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Triple-Negative Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Carcinoma, Squamous Cell | Phase 1 | 2016-08-12 |
| Terminated | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | 2016-08-01 |
| Completed | Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatas Breast Neoplasms | Phase 2 | 2016-07-28 |
| Terminated | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia Acute Myelogenous Leukemia | Phase 1 / Phase 2 | 2015-03-09 |
| Completed | Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2014-09-15 |
| Completed | Study of the Glutaminase Inhibitor CB-839 in Leukemia Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL) | Phase 1 | 2014-03-01 |
| Completed | Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Wome Breast Cancer | Phase 2 | 2014-02-13 |
| Completed | Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM) | Phase 1 | 2014-02-01 |
| Completed | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer | Phase 1 | 2014-02-01 |
| Completed | A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies Advanced Solid Tumor and Lymphoma Malignancies | Phase 1 | 2013-12-31 |